顺铂联合紫杉醇治疗复发宫颈癌的效果观察、毒性反应及护理

Efficacy,toxicity and nursing of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer

目的研究顺铂联合紫杉醇治疗复发宫颈癌的临床效果、毒性反应及护理。方法选择2017年5月至2019年5月于天津医科大学第二医院就诊的宫颈癌复发患者60例,随机分为对照组和研究组。对照组给予紫杉醇化疗和常规护理,研究组给予顺铂联合紫杉醇治疗和临床毒性反应护理。治疗后,对两组患者的总有效率,炎性因子C-反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞计数(WBC)及红细胞沉降率(ESR)水平和毒性反应进行评价。结果研究组治疗复发宫颈癌的总有效率为93.3%,明显高于对照组的73.3%,差异具有统计学意义(P<0.05)。研究组的CRP、IL-6、WBC和ESR炎性指标水平均低于对照组,差异均具有统计学意义(均P<0.05)。研究组的毒性反应发生率为10.0%,低于对照组的36.7%,差异具有统计学意义(P<0.05)。结论顺铂联合紫杉醇治疗复发宫颈癌并实施临床毒性反应护理,可提高治疗的有效率、降低各种炎性指标水平以及毒性反应发生率,安全性高,从而延长患者的生存时间,值得临床推广应用。

Objective To explore and evaluate the effect of clinical toxicity nursing on the therapeutic effect of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer.Methods Sixty patients with recurrent cervical cancer treated in the Second Hospital of Tianjin Medical University from May 2017 to May 2019 were randomly divided into two groups.The control group was given paclitaxel chemotherapy and routine nursing,and the study group was given paclitaxel combined with cisplatin and clinical toxicity nursing.Results In the study group,the total effective rate of 93.3%was significantly higher than that of 73.3%in the control group(P<0.05),and the levels of inflammatory indexes,including C-reactive protein(CRP),interleukin-6(IL-6),white blood cell(WBC)and erythrocyte sedimentation rate(ESR)in the study group were lower than those in the control group(P<0.05).The incidence of toxicity in the study group was 10.0%lower than that in the control group(36.7%,P<0.05).Conclusions The use of paclitaxel combined with cisplatin chemotherapy for recurrent cervical cancer and clinical toxic reaction nursing can improve the effectiveness rate of treatment,reduce the levels of various inflammatory indicators,and reduce the incidence of toxic reactions with high safety,thus prolonging the survival time of patients,making it worthy of clinical application.